As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.
5 Analysts have issued a BriaCell Therapeutics Corp forecast:
5 Analysts have issued a BriaCell Therapeutics Corp forecast:
| Jul '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -27 -27 |
19%
19%
|
|
| EBIT (Operating Income) EBIT | -27 -27 |
18%
18%
|
|
| Net Profit | -26 -26 |
486%
486%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
| Head office | Canada |
| CEO | William Williams |
| Employees | 16 |
| Founded | 2006 |
| Website | briacell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


